Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAWNNASDAQ:DMACNASDAQ:OCSNASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$8.07-1.5%$10.60$7.88▼$18.07$817.94M-1.381.10 million shs598,146 shsDMACDiaMedica Therapeutics$3.82-7.7%$5.83$2.14▼$6.82$163.71M1.5271,709 shs160,051 shsOCSOculis$19.18-1.1%$20.66$10.55▼$23.08$837.44M0.0146,226 shs35,765 shsREPLReplimune Group$10.39-0.6%$12.67$4.92▼$17.00$800.19M1.3858,281 shs368,583 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals0.00%-1.94%-10.93%-35.85%-51.15%DMACDiaMedica Therapeutics0.00%-23.29%-41.50%-28.46%+37.91%OCSOculis0.00%-1.99%-2.04%+13.02%+59.17%REPLReplimune Group0.00%-3.97%-18.06%-15.73%+27.17%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDAWNDay One Biopharmaceuticals2.9136 of 5 stars4.62.00.00.01.92.50.0DMACDiaMedica Therapeutics1.7176 of 5 stars3.53.00.00.02.30.00.0OCSOculis1.7763 of 5 stars3.53.00.00.01.30.00.6REPLReplimune Group3.8244 of 5 stars3.60.00.04.53.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAWNDay One Biopharmaceuticals 3.13Buy$32.29300.07% UpsideDMACDiaMedica Therapeutics 3.00Buy$8.00109.42% UpsideOCSOculis 3.00Buy$29.5053.81% UpsideREPLReplimune Group 3.13Buy$19.4386.99% UpsideCurrent Analyst Ratings BreakdownLatest DMAC, DAWN, REPL, and OCS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.003/19/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/13/2025OCSOculisRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$37.00 ➝ $41.003/13/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/13/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $29.003/5/2025DAWNDay One BiopharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$39.00 ➝ $34.002/26/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$32.00 ➝ $32.002/26/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.002/26/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $36.002/26/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $18.002/13/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAWNDay One Biopharmaceuticals$131.16M6.24N/AN/A$3.98 per share2.03DMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AOCSOculis$980K854.53N/AN/A$2.87 per share6.68REPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAWNDay One Biopharmaceuticals-$188.92M-$1.08N/AN/AN/AN/A-22.40%-19.79%5/5/2025 (Estimated)DMACDiaMedica Therapeutics-$19.38M-$0.60N/AN/AN/AN/A-43.67%-40.81%5/6/2025 (Estimated)OCSOculis-$98.92M-$2.31N/AN/AN/A-8,043.28%-71.31%-56.85%5/14/2025 (Estimated)REPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%5/15/2025 (Estimated)Latest DMAC, DAWN, REPL, and OCS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/17/2025Q4 2024DMACDiaMedica Therapeutics-$0.17-$0.18-$0.01-$0.18N/AN/A3/11/2025Q4 2024OCSOculis-$0.48-$0.76-$0.28-$0.76$0.21 millionN/A2/25/2025Q4 2024DAWNDay One Biopharmaceuticals-$0.35-$0.69-$0.34-$0.69$27.11 million$29.21 million2/12/2025Q3 2025REPLReplimune Group-$0.70-$0.79-$0.09-$0.79N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAWNDay One BiopharmaceuticalsN/A14.6214.55DMACDiaMedica TherapeuticsN/A11.8111.81OCSOculis0.014.024.02REPLReplimune Group0.1411.4311.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAWNDay One Biopharmaceuticals87.95%DMACDiaMedica Therapeutics10.12%OCSOculis22.30%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipDAWNDay One Biopharmaceuticals8.40%DMACDiaMedica Therapeutics7.20%OCSOculisN/AREPLReplimune Group8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableDMACDiaMedica Therapeutics2042.86 million39.68 millionOptionableOCSOculis243.66 millionN/ANot OptionableREPLReplimune Group21077.02 million70.24 millionOptionableDMAC, DAWN, REPL, and OCS HeadlinesRecent News About These Companies611,013 Shares in Replimune Group, Inc. (NASDAQ:REPL) Purchased by Artisan Partners Limited PartnershipMarch 30 at 4:59 AM | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Swiss National BankMarch 30 at 3:17 AM | marketbeat.comCharles Schwab Investment Management Inc. Has $6.16 Million Stake in Replimune Group, Inc. (NASDAQ:REPL)March 25, 2025 | marketbeat.comRosalind Advisors Inc. Purchases New Position in Replimune Group, Inc. (NASDAQ:REPL)March 23, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Down 5.6% - What's Next?March 22, 2025 | marketbeat.comVictory Capital Management Inc. Purchases Shares of 44,880 Replimune Group, Inc. (NASDAQ:REPL)March 22, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by BrokeragesMarch 17, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Up 6.4% - Still a Buy?March 13, 2025 | marketbeat.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | globenewswire.comNew York State Common Retirement Fund Purchases 31,231 Shares of Replimune Group, Inc. (NASDAQ:REPL)March 5, 2025 | marketbeat.comLos Angeles Capital Management LLC Lowers Position in Replimune Group, Inc. (NASDAQ:REPL)March 4, 2025 | marketbeat.comReplimune price target raised to $18 from $16 at JPMorganFebruary 26, 2025 | markets.businessinsider.comReplimune price target raised to $22 from $21 at H.C. WainwrightFebruary 13, 2025 | markets.businessinsider.comNavigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global RisksFebruary 13, 2025 | msn.comReplimune stock target raised to $22 at H.C. WainwrightFebruary 13, 2025 | msn.comBarclays Keeps Their Buy Rating on Replimune Group (REPL)February 13, 2025 | markets.businessinsider.comReplimune price target raised to $19 from $16 at WedbushFebruary 12, 2025 | markets.businessinsider.comReplimune price target raised to $21 from $18 at LeerinkFebruary 12, 2025 | markets.businessinsider.comReplimune: A Misunderstood Contender In OncolyticsFebruary 12, 2025 | seekingalpha.comReplimune reports Q3 EPS (79c) vs (77c) last yearFebruary 12, 2025 | markets.businessinsider.comReplimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate UpdateFebruary 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMAC, DAWN, REPL, and OCS Company DescriptionsDay One Biopharmaceuticals NASDAQ:DAWN$8.07 -0.12 (-1.47%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$8.07 0.00 (0.00%) As of 03/28/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.DiaMedica Therapeutics NASDAQ:DMAC$3.82 -0.32 (-7.73%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$3.82 +0.01 (+0.13%) As of 03/28/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Oculis NASDAQ:OCS$19.18 -0.22 (-1.13%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$19.18 0.00 (0.00%) As of 03/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Replimune Group NASDAQ:REPL$10.39 -0.06 (-0.57%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$10.39 0.00 (0.00%) As of 03/28/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
